PMID: 16520474Mar 8, 2006Paper

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine
Julio SoteloMiguel Angel López-González

Abstract

Malignant cell clones resistant to chemotherapy and radiotherapy frequently lead to treatment failure in patients with glioblastoma multiforme. Preliminary studies suggest that adding chloroquine to conventional therapy may improve treatment outcomes. To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme. Randomized, double-blind, placebo-controlled trial. National Institute of Neurology and Neurosurgery of Mexico. 30 patients with surgically confirmed glioblastoma confined to 1 cerebral hemisphere, with a Karnofsky performance score greater than 70, no comorbid disease, and age younger than 60 years. Oral chloroquine at 150 mg/d for 12 months beginning on postoperative day 5 or placebo. All patients received conventional chemotherapy and radiotherapy. Primary outcome was survival after surgery; surviving patients were followed up to October 2005. Periodic evaluation using the Karnofsky scale and imaging studies, as well as hematologic tests and ophthalmologic examinations, was done in all patients. Median survival after surgery was 24 months for chloroquine-treated patients and 11 months for controls. At the end of the observation period, 6 patients treated with chloroquine had survive...Continue Reading

Citations

Apr 17, 2008·Lupus·G Ruiz-Irastorza, M A Khamashta
Dec 18, 2010·Nature Chemical Biology·Angeleen FlemingDavid C Rubinsztein
Oct 21, 2010·Physiological Reviews·Brinda RavikumarDavid C Rubinsztein
Dec 15, 2012·Apoptosis : an International Journal on Programmed Cell Death·Claudia FioriniMassimo Donadelli
Dec 20, 2012·Molecular Endocrinology·Yan ShiDaniel E Frigo
Aug 15, 2013·Pharmacological Reviews·Yan ChengJin-Ming Yang
Jun 14, 2013·The Journal of General and Applied Microbiology·Ravikumar B ShindeS Mohan Karuppayil
Jul 23, 2013·The Cancer Journal·Michael T LotzeLeonard Appleman
Oct 1, 2013·Acta Pharmacologica Sinica·Shyang-guang WangYuan-nian Hsu
Dec 2, 2014·Neurosurgical Focus·Encouse B GoldenThomas C Chen
Mar 31, 2015·Oncology Reports·Uddin Md NazimSang-Youel Park
Oct 21, 2015·Nature Reviews. Clinical Oncology·Francesco BertoliniGauthier Bouche
Jan 9, 2016·Critical Reviews in Clinical Laboratory Sciences·Subhadip MukhopadhyaySujit Kumar Bhutia
Jan 1, 2014·Molecular & Cellular Oncology·Gwenola ManicLorenzo Galluzzi
May 2, 2017·Frontiers in Oncology·Devrim GozuacikMuhammed Kocak
Jul 29, 2017·Nature Reviews. Cancer·Jean M Mulcahy LevyAndrew Thorburn
Oct 4, 2017·The Journal of Clinical Endocrinology and Metabolism·Shao Jian LinZhe Bao Wu
Oct 6, 2017·Cancer Chemotherapy and Pharmacology·Panagiotis SamarasSteve Pascolo
Jul 4, 2018·Signal Transduction and Targeted Therapy·Qi ChenCaiyun Fu
Aug 30, 2018·Cancer Science·Taisuke AkimotoYoshihiro Ishikawa
Jan 10, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Kuo-Hao HoKu-Chung Chen
Sep 23, 2009·Annals of the New York Academy of Sciences·Clara LocherLaurence Zitvogel
Mar 29, 2008·Lupus·A Doria, C Briani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.